Personalized treatment selection for metastatic breast cancer

Trial Profile

Personalized treatment selection for metastatic breast cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2015

At a glance

  • Drugs Dasatinib (Primary) ; Selumetinib (Primary)
  • Indications Advanced breast cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 17 Jul 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 30 May 2014 Status changed from active, no longer recruiting to completed; according to ClinicalTrials.gov record.
    • 13 Nov 2012 Planned number of patients changed from 532 to 769 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top